US equities |
MU $913.87 ▲+4.14% TSLA $394.39 ▲+5.96% NVDA $216.41 ▲+2.58% SPCX $148.81 ▲+0.89% META $634.94 ▼-1.20% AAPL $343.50 ▼-1.21% SNDK $1,273.73 ▲+2.88% INTC $91.85 ▲+5.62%
FinancialContent

Inovio Pharmaceuticals, Inc. - Common Stock (NQ:INO)

0.8776 -0.0195 (-2.17%)
Delayed Quote Updated: 2:21 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inovio Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
After-Hours Movers: Postmarket Gainers and Losers ↗
Via Chartmill
News headline image
Inovio Nears FDA Decision on INO-3107 as Oct. 30 PDUFA Date Looms ↗
Inovio Pharmaceuticals (NASDAQ:INO) said its biologics license application for INO-3107, an investigational DNA medicine for recurrent respiratory papillomatosis, or RRP, remains under U.S. Food and... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Inovio Pharmaceuticals Nears Oct. 30 FDA Decision for INO-3107 in RRP ↗
Inovio Pharmaceuticals (NASDAQ:INO) is approaching an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP, President and CEO Jacky Shea... 
Via MarketBeat
News headline image
Inovio (INO) Q2 2026 Earnings Call Transcript ↗
INO-3107 advances toward October FDA decision as company extends cash runway through early 2027. 
Via The Motley Fool
Topics Earnings
News headline image
Inovio Pharmaceuticals Q2 Earnings Call Highlights ↗
Inovio Pharmaceuticals (NASDAQ:INO) said the U.S. Food and Drug Administration has completed several key steps in its review of the company’s biologics license application for INO-3107, an... 
Via MarketBeat
Topics Earnings
Here are the top movers in Thursday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
Via Chartmill
News headline image
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances ↗
Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young... 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Inovio (INO) Q1 2026 Earnings Call Transcript ↗
Inovio (INO) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Biotech Stocks Rally on Hantavirus Fears: Is the Surge Overdone? ↗
Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week. 
Via The Motley Fool
Topics Death
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Inovio Deadline Today: Rosen Law Firm Urges Inovio Pharmaceuticals, Inc. (NASDAQ: INO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
INO CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Urgently Reminds Investors that a Class Action Lawsuit Has Been Filed Against Inovio Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before April 7th
From Bragar Eagel & Squire
Via GlobeNewswire
On Monday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
Deadline Soon: Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-04-02: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
What's Behind The Drop In Inovio Pharmaceuticals Stock Today? ↗
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares are tumbling Thursday after the company announced the pricing of a proposed public offering. 
Via Benzinga
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers – INO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INOVIO DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >